Key Takeaway: Dr. Jonathan Javitt, the Founder, Chairman, and CEO of NRx Pharmaceuticals, participated in a broadcast hosted by AdvisorShares. The broadcast highlights NRx's connection with institutional investors, specifically AdvisorShares, who hold NRXP stock. No additional details regarding the content of the interview were provided.
Price reaction · baseline $3.3065 (2025-10-06T17:13:00.000Z) · hit during market hours · 1 other NRXP headline(s) in the window, move may be shared
day 0 close · peak
+1.3%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+167%
120-day peak, hindsight
Typical move
4.3%
average across 2 past catalysts
Cash runway
~12 mo
Low dilution risk
Lead asset
NRX-101
Phase 2 · Bipolar Depression
Full Press Release Details
Oct. 6, 2025 News - Broadcasts NRx News AdvisorShares is an institutional investor and holder of NRXP stock. <span style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" data-mce-type="bookmark" class="mce_SELRES_start"></span> Share